GMJ Briefs
Announcement: Eli Lilly’s Gene Editor Cuts Cholesterol 62% in First Human Trial
🧬 BREAKTHROUGH: Eli Lilly's gene-editing therapy cuts cholesterol by 62% with a single dose! VERV-102 targets the PCSK9 gene for…
Complete Developmental Arrest Observed When Master Biological Clock Fails
Experimental disruption of the genetic master clock results in complete developmental arrest, revealing its critical regulatory role.
Four Decades of Cardiac Protocol Under Review: International Trial Questions Beta Blocker Use Post-Heart Attack
International study of 5,020 patients challenges 40-year-old beta blocker protocol for uncomplicated heart attacks.
Critical Juncture: Microglial Transitions Determine Dementia vs. Cognitive Resilience
Microglial cellular transitions at the amyloid-tau junction emerge as the key determinant of cognitive outcomes in aging.
First Pro Sports League Openly Embraces Performance-Enhancing Drugs, Drawing IOC Condemnation
Las Vegas hosts first major sporting event explicitly permitting performance-enhancing drugs, prompting widespread medical and ethical concerns.
Heat Stress and Classroom Performance: New Data on Climate’s Cognitive Impact
Just 1°C above seasonal temperature averages reduces academic performance in low-income schools, with reading scores dropping 15% above 32°C.
Clinical Studies Confirm Perimenopause Brain Fog Is Real Biology, Not Psychology
New clinical evidence confirms perimenopause brain fog reflects measurable cognitive decline rooted in biological hormone fluctuations rather than psychological causes.
The Lean Diabetes Paradox: Why Normal Weight Doesn’t Guarantee Protection
Five percent of diabetes cases develop in lean individuals, revealing metabolic risk independent of body weight.